NEWS
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
Thursday, 12th December at 8:00 am
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -
- IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma -
- Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 -
Thursday, 12th December at 8:00 am
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors -
- IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma -
- Melanoma patients actively enrolling in one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
3700Followers
73Following
41KVisitors
Follow